Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 7NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Colonic Neoplasms 226Colorectal Neoplasms 203Rectal Neoplasms 194Pancreatic Neoplasms 158Carcinoma, Hepatocellular 109Stomach Neoplasms 94Esophageal Neoplasms 81Liver Neoplasms 72Breast Neoplasms 68Lung Neoplasms 53Neoplasms 48Carcinoma, Non-Small-Cell Lung 47Neoplasm Metastasis 46Ovarian Neoplasms 44Sarcoma 43Bile Duct Neoplasms 38Gallbladder Neoplasms 37Melanoma 33Anus Neoplasms 31Prostatic Neoplasms 30Adenocarcinoma Of Esophagus 29Lymphoma, Non-Hodgkin 28Carcinoma, Renal Cell 28Uterine Cervical Neoplasms 27Osteosarcoma 27Gastrointestinal Stromal Tumors 27Gastrointestinal Neoplasms 27Neuroectodermal Tumors, Primitive, Peripheral 25Neuroblastoma 25Wilms Tumor 24

Interventions

cabozantinib 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Non functioning pancreatic endocrine tumor × Gastrointestinal × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡